Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review

FDA is evaluating clinical trial data that may suggest that patients taking Stalevo may be at an increased risk for developing prostate cancer.

Related Posts:

1. Benicar (olmesartan): Ongoing Safety Review
2. Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety
3. Genetic Link To Mesothelioma Discovered
4. Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures
5. Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp: Drug Safety Communication